Anticancer Activity of Apaziquone in Oral Cancer Cells and Xenograft Model: Implications for Oral Cancer Therapy

• Gunjan Srivastava,

  Affiliation Alex and Simona Shnaider Research Laboratory in Molecular Oncology, Mount Sinai Hospital, Toronto, Canada

  ⨯
• Raj Thani Somasundaram,

  Affiliation Alex and Simona Shnaider Research Laboratory in Molecular Oncology, Mount Sinai Hospital, Toronto, Canada

  ⨯
• Paul G. Walfish,

  Affiliations Alex and Simona Shnaider Research Laboratory in Molecular Oncology, Mount Sinai Hospital, Toronto, Canada, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada, Joseph and Mildred Sonshine Family Centre for Head and Neck Diseases, Department of Otolaryngology—Head and Neck Surgery, Mount Sinai Hospital, Toronto, Canada, Department of Medicine, Endocrine Division, Mount Sinai Hospital and University of Toronto, Toronto, Canada, Department of Otolaryngology—Head and Neck Surgery, University of Toronto, Toronto, Canada

  ⨯
• Ranju Ralhan

  * E-mail: rralhan@mtsinai.on.ca

  Affiliations Alex and Simona Shnaider Research Laboratory in Molecular Oncology, Mount Sinai Hospital, Toronto, Canada, Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Canada, Joseph and Mildred Sonshine Family Centre for Head and Neck Diseases, Department of Otolaryngology—Head and Neck Surgery, Mount Sinai Hospital, Toronto, Canada, Department of Otolaryngology—Head and Neck Surgery, University of Toronto, Toronto, Canada

  ⨯